An open prospective study of amikacin pharmacokinetics in critically ill patients during treatment with continuous venovenous haemodiafiltration.

scientific article

An open prospective study of amikacin pharmacokinetics in critically ill patients during treatment with continuous venovenous haemodiafiltration. is …
instance of (P31):
scholarly articleQ13442814

External links are
P6179Dimensions Publication ID1039523511
P356DOI10.1186/2050-6511-13-14
P932PMC publication ID3517742
P698PubMed publication ID23136834
P5875ResearchGate publication ID233382799

P50authorDeirdre M D'ArcyQ57250442
P2093author name stringOwen I Corrigan
Eoin Casey
Maria B Donnelly
Caitriona M Gowing
P2860cites workA prospective randomized study comparing once- versus twice-daily amikacin dosing in critically ill adult and paediatric patientsQ28325426
Amikacin monotherapy for sepsis caused by panresistant Pseudomonas aeruginosaQ34290150
Population pharmacokinetics of amikacin in critically ill patientsQ35125654
Once-daily amikacin dosing in burn patients treated with continuous venovenous hemofiltrationQ35270646
Multiple-dose pharmacokinetics of amikacin and ceftazidime in critically ill patients with septic multiple-organ failure during intermittent hemofiltrationQ35810241
Pharmacokinetic considerations for antimicrobial therapy in patients receiving renal replacement therapyQ37008814
Antibiotic resistance--what's dosing got to do with it?Q37205795
Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysisQ37461431
Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentrationQ44483617
Population pharmacokinetics of aminoglycosides in critically ill trauma patients on once-daily regimens.Q52071390
Pharmacokinetics of a loading dose of amikacin in septic patients undergoing continuous renal replacement therapyQ64126632
Implications of augmented renal clearance in critically ill patientsQ64129339
Pharmacokinetics of dosing regimens which utilize multiple intravenous infusions: gentamicin in burn patientsQ67779622
Pharmacokinetics of amikacin during continuous veno-venous hemofiltrationQ68796364
Amikacin pharmacokinetics: wide interpatient variation in 98 patientsQ70129560
Amikacin pharmacokinetics during continuous veno-venous hemofiltrationQ70141346
Association of aminoglycoside plasma levels with therapeutic outcome in gram-negative pneumoniaQ70386358
Expanded gentamicin volume of distribution in critically ill adult patients receiving total parenteral nutritionQ70937793
Relationship between hemodynamic and vital support measures and pharmacokinetic variability of amikacin in critically ill patients with sepsisQ73425751
P921main subjecthemodiafiltrationQ3144940
pharmacokineticsQ323936
amikacinQ408529
P304page(s)14
P577publication date2012-11-08
P1433published inBMC pharmacology & toxicologyQ27724429
P1476titleAn open prospective study of amikacin pharmacokinetics in critically ill patients during treatment with continuous venovenous haemodiafiltration
P478volume13

Reverse relations

cites work (P2860)
Q40809870A high-dose aminoglycoside regimen combined with renal replacement therapy for the treatment of MDR pathogens: a proof-of-concept study.
Q33939050Amikacin pharmacokinetics during continuous veno-venous hemodialysis
Q86490988Gentamicin pharmacokinetics in critically ill patients during treatment with continuous venovenous haemodiafiltration (CVVHDF)
Q49894608Implication of Haemodiafiltration Flow Rate on Amikacin Pharmacokinetic Parameters in Critically Ill Patients
Q37119964Influence of Renal Replacement Modalities on Amikacin Population Pharmacokinetics in Critically Ill Patients on Continuous Renal Replacement Therapy
Q88214372What is new in the use of aminoglycosides in critically ill patients?

Search more.